Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1519033 | 0.98 | CYP1A2 (0.33) | SIGMAR1SMN1; SMN2POLBCXCR4CHRM5 | |
| SCHEMBL2380462 | 0.88 | — | — | |
| SCHEMBL2385305 | 0.84 | — | — | |
| SCHEMBL2384105 | 0.84 | — | — | |
| SCHEMBL4002631 | 0.82 | SIGMAR1 (0.33) | SIGMAR1SMN1; SMN2POLBCXCR4CHRM5 | |
| SCHEMBL538138 | 0.82 | SIGMAR1 (0.36) | SIGMAR1SMN1; SMN2POLBCXCR4CHRM5 | |
| SCHEMBL2383064 | 0.80 | ALDH1A1 (0.30) | — | |
| SCHEMBL2381809 | 0.80 | — | — | |
| SCHEMBL4005712 | 0.80 | SIGMAR1 (0.35) | SIGMAR1SMN1; SMN2POLBCYP1A2CHRM2 | |
| SCHEMBL4061260 | 0.80 | POLB (0.38) | SIGMAR1SMN1; SMN2POLBCXCR4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7569691-B2 | Protected piperazino group-bearing organoxysilane compound and making method | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2009-08-04 | — | — | US | claimed |
| US-12545809-B2 | Moisture-curing conformal coating compositions | WACKER CHEMIE AG (DE) | 2026-02-10 | — | — | US | disclosed |
| WO-2025223681-A1 | CROSS-LINKABLE COMPOSITIONS ON THE BASIS OF ORGANOSILICON COMPOUNDS | WACKER CHEMIE AG (DE) | 2025-10-30 | — | — | WO | disclosed |
| EP-4499747-B1 | CROSS-LINKABLE COMPOSITIONS ON THE BASIS OF ORGANOSILICON COMPOUNDS | WACKER CHEMIE AG (DE) | 2025-10-29 | — | — | EP | disclosed |
| US-12448487-B2 | Polysiloxanes with radiation- and moisture-cross-linkable groups | WACKER CHEMIE AG (DE) | 2025-10-21 | — | — | US | disclosed |
| US-20250215158-A1 | Cross-linkable compositions on the basis of organosilicon compounds | WACKER CHEMIE AG (DE) | 2025-07-03 | — | — | US | disclosed |
| EP-4499747-A1 | CROSS-LINKABLE COMPOSITIONS ON THE BASIS OF ORGANOSILICON COMPOUNDS | Wacker Chemie AG (DE) | 2025-02-05 | — | — | EP | disclosed |
| CN-118974157-A | Crosslinkable compositions based on organosilicon compounds | 瓦克化学股份公司 | 2024-11-15 | — | — | CN | disclosed |
| EP-4172246-B1 | MOISTURE-CURING CONFORMAL COATING COMPOSITIONS | WACKER CHEMIE AG (DE) | 2024-08-07 | — | — | EP | disclosed |
| CN-115397891-B | Polysiloxanes with radiation-crosslinkable and moisture-crosslinkable groups | 瓦克化学股份公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-1950458-A | Moisture cross-linking composition containing alkoxysilyl functional particles | CONSORTIUM ELEKTROCHEM IND (DE) | 2007-04-18 | — | — | CN | disclosed |
| EP-1745107-A2 | MOISTURE CROSS-LINKING COMPOSITION CONTAINING ALKOXYSILYL FUNCTIONAL PARTICLES | Consortium für elektrochemische Industrie GmbH (DE) | 2007-01-24 | — | — | EP | disclosed |
| US-20060258820-A1 | Process for preparing dispersions of crosslinked organopolysiloxanes | WACKER CHEMIE AG (DE) | 2006-11-16 | — | — | US | disclosed |
| WO-2006119916-A1 | METHOD FOR PRODUCING CROSSLINKABLE ORGANOPOLYSILOXANE DISPERSIONS | WACKER CHEMIE AG (DE) | 2006-11-16 | — | — | WO | disclosed |
| EP-1721926-A1 | Process for the production of dispersions of cross linked organopolysiloxanes | Wacker Chemie AG (DE) | 2006-11-15 | — | — | EP | disclosed |
| US-20060241294-A1 | Protected piperazino group-bearing organoxysilane compound and making method | SHIN-ETSU CHEMICAL CO., LTD. | 2006-10-26 | — | — | US | disclosed |
| EP-1714968-A1 | Protected piperazino group-bearing organoxysilane compound and making method | Shin-Etsu Chemical Co., Ltd. (JP) | 2006-10-25 | — | — | EP | disclosed |
| WO-2006061091-A2 | HIGHLY REACTIVE $G(A)-AMINOMETHYL-ALKOXYSILANES HAVING IMPROVED STABILITY | WACKER CHEMIE AG (DE) | 2006-06-15 | — | — | WO | disclosed |
| WO-2006061090-A1 | ALKOXYSILANE-TERMINATED PREPOLYMERS | WACKER CHEMIE AG (DE) | 2006-06-15 | — | — | WO | disclosed |
| WO-2005108495-A2 | MOISTURE CROSS-LINKING COMPOSITION CONTAINING ALKOXYSILYL FUNCTIONAL PARTICLES | Consortium für elektrochemische Industrie GmbH (DE) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241294-A1 | Protected piperazino group-bearing organoxysilane compound and making method | PIEZO1, VCL, VIM | SIGMAR1 1050/4885SMN1; SMN2 1719/4885POLB 1859/4885 |
| US-12545809-B2 | Moisture-curing conformal coating compositions | COL1A1, COL2A1, MSR1 | SIGMAR1 42/4885SMN1; SMN2 181/4885POLB 2336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.